- ISIN
- US03843E1047
- CUSIP
- 03843E104
- Sector
- Healthcare
- IPO Date
- Jul 25, 2018
Highlights
- Market Cap
- $463.60M
- Enterprise Value
- $410.77M
- EPS (TTM)
- -$0.58
- Total Revenue (TTM)
- $50.27M
- Gross Profit (TTM)
- $20.92M
- EBITDA (TTM)
- -$53.08M
- Year Range
- $2.93 - $7.55
- Target Price
- $9.00
- ROA (TTM)
- -48.83%
- ROE (TTM)
- 202.36%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $7.26M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AQST Performance Chart
Aquestive Therapeutics, Inc. (AQST) is down 42.8% since the beginning of the year. At $4 per share, AQST is trading 51.1% below its 52-week high of $8. Investors who bought $1,000 worth of AQST shares 5 years ago would now be looking at an investment worth $1,137.
Loading charts...
Compare this symbol against anything
Returns By Period
Aquestive Therapeutics, Inc. (AQST) has returned -42.80% so far this year and -3.27% over the past 12 months.
Aquestive Therapeutics, Inc.
- 1D
- -0.67%
- 1M
- -11.60%
- 6M
- 25.25%
- YTD
- -42.80%
- 1Y
- -3.27%
- 3Y*
- 18.16%
- 5Y*
- 2.60%
- 10Y*
- —
- ALL TIME*
- -16.07%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AQST Monthly Returns History
Based on dividend-adjusted daily data since Jul 25, 2018, AQST's average daily return is +0.08%, while the average monthly return is +2.44%. At this rate, an investment would double in approximately 2.4 years.
Historically, 44% of months were positive and 56% were negative. The best month was Nov 2019 with a return of +102.9%, while the worst month was Jan 2026 at -54.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, AQST closed higher 46% of trading days. The best single day was Feb 2, 2026 with a return of +39.0%, while the worst single day was Jan 9, 2026 at -37.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -54.33% | 35.59% | 3.75% | -1.20% | -1.95% | 3.48% | -11.18% | -42.80% | |||||
| 2025 | -15.17% | -7.28% | 3.57% | 0.86% | -7.35% | 22.14% | 16.01% | -1.82% | 48.28% | 22.00% | -9.24% | 4.36% | 81.46% |
| 2024 | 18.32% | 53.56% | 16.08% | -21.13% | -14.29% | -9.72% | 47.69% | 17.97% | 9.93% | 10.24% | -7.29% | -30.06% | 76.24% |
| 2023 | -1.34% | -12.08% | 45.69% | 17.54% | 72.39% | -28.57% | 32.73% | -25.11% | -6.71% | 2.61% | 43.31% | -10.22% | 123.92% |
| 2022 | -30.08% | 2.57% | -6.45% | -46.36% | -29.00% | -35.63% | 28.48% | 75.79% | -19.03% | -25.64% | 6.67% | -2.79% | -76.81% |
| 2021 | -1.12% | -13.42% | 13.54% | -21.73% | -8.85% | 7.01% | -18.14% | 40.92% | -4.80% | 17.89% | 14.79% | -34.07% | -27.29% |
Benchmark Metrics
Aquestive Therapeutics, Inc. has an annualized alpha of 3.57%, beta of 1.23, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 25, 2018.
- This stock participated in 190.59% of S&P 500 Index downside but only 105.82% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 3.57%
- Beta
- 1.23
- R²
- 0.08
- Upside Capture
- 105.82%
- Downside Capture
- 190.59%
Return for Risk
Risk / Return Rank
AQST ranks 45 for risk / return — above 45% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Aquestive Therapeutics, Inc. (AQST) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AQST | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.46 | ||
| Sortino ratioReturn per unit of downside risk | -1.39 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.25 | -0.17 |
| Calmar ratioReturn relative to maximum drawdown | -0.06 | 2.00 | -2.07 |
| Martin ratioReturn relative to average drawdown | -0.11 | 8.49 | -8.60 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aquestive Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aquestive Therapeutics, Inc. was 96.68%, occurring on Jul 1, 2022. The portfolio has not yet recovered.
The current Aquestive Therapeutics, Inc. drawdown is 80.51%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.68%Jul 2022 | 3y 9mo | — | 7y 10moSep 2018 - now | Bear market2022 |
-6.54%Aug 2018 | 11d | 7d | 18dJul 2018 - Aug 2018 | — |
-6.17%Aug 2018 | 12d | 2d | 14dAug 2018 - Aug 2018 | — |
-0.67%Sep 2018 | 1d | 2d | 2dSep 2018 - Sep 2018 | Rate-hike selloffLate 2018 |
Drawdown Indicators
| AQST | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.68% | -56.78% | -39.90% |
Max Drawdown (1Y)Largest decline over 1 year | -60.61% | -9.10% | -51.51% |
Max Drawdown (3Y)Largest decline over 3 years | -63.55% | -18.90% | -44.65% |
Max Drawdown (5Y)Largest decline over 5 years | -90.11% | -25.43% | -64.68% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -80.51% | -1.58% | -78.93% |
Average DrawdownAverage peak-to-trough decline | -76.94% | -10.70% | -66.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 35.71% | 2.14% | +33.57% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aquestive Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Aquestive Therapeutics, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AQST relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AQST has a P/S ratio of 8.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AQST
Add Aquestive Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AQST